Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Lorigerlimab for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma in Patients with Homologous Recombination Deficiency

Trial Status: active

This phase II trial studies how well lorigerlimab works in treating patients with pancreatic ductal adenocarcinoma (PDAC) that has spread from where it first started (primary site) to other places in the body (metastatic) and that has changes (mutations) in the BRCA1, BRCA2, PALB2, RAD51C, and RAD51D genes (homologous recombination deficiency). Immunotherapy with monoclonal antibodies, such as lorigerlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.